/

ICCC

ImmuCell CorporationPre-market

10.79+1.19 +12.40%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

10.50

Prev close

9.60

Day range

10.1510.80

52-week range

4.5212.10

Volume

50.26K2.42×

Mkt cap

98.00M

P/E ttm

154.14

Fwd P/E

-98.09

EPS ttm

0.0700

Div yield

0.00%

Earnings

Nov 12, 2026

From 52w high

−10.83%

Price Chart

Yahoo Finance · delayed

ICCCOct 13, 2026O 10.79H 10.80L 10.15C 10.79+1.19 (+12.40%)Vol 50.30K

SMA 5010.07
SMA 2008.59

1Y change +63.98% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ICCC ImmuCell Corporation · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +8.22%
1 month: +9.54%
3 months: −7.94%
6 months: +39.59%
Year to date: +75.45%
1 year: +63.98%

Valuation & ownership

Market cap: 98.00M
Enterprise value: 101.58M
P/E (ttm): 154.14
Forward P/E: -98.09
PEG ratio: —
Price / book: 3.12
Price / sales (ttm): 3.19
EV / EBITDA: 14.41
EPS (ttm): 0.0700
EPS (forward): -0.1100
Beta (5y monthly): 0.57
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 9.08M
Float: 6.03M
Short % of float: 0.29%
Short ratio (days): 1.69
Held by insiders: 32.09%
Held by institutions: 20.30%
Avg volume (3m): 20.80K
50-day average: 10.07
200-day average: 8.57
52-week change: +63.98%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 66.5
vs 50-day SMA: +7.18%
vs 200-day SMA: +25.57%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.05%
Realised vol (20d, ann.): 48.4%
From 52-week high: −10.83%
From 52-week low: +138.72%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 30.68M
Revenue growth (yoy): +11.50%
Earnings growth (yoy): +259.90%
Gross margin: 40.32%
Operating margin: 26.93%
Profit margin: 2.57%

DES

About ImmuCell Corporation

Yahoo Finance profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Sector: Healthcare
Industry: Biotechnology
Employees: 73
Headquarters: Portland, ME, United States
Website: immucell.com
Officers: Mr. Paul F. Olivier Te Boekhorst President, CEO & Director
Mr. Timothy C. Fiori CFO, Secretary & Treasurer
Ms. Bobbi Jo Brockmann Senior Vice President of Sales & Marketing

SEAS

Seasonality · ICCC

2007–2026 · monthly returns

Strongest month Jun +9.82%Weakest month Aug −4.17%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.1	9.1	-3.7	33.6	21.0	-1.9	11.5	-12.7	0.1	10.1			+75.4%
2025	4.9	-2.2	-9.3	13.2	18.1	8.7	-8.5	0.5	-2.3	-0.2	-22.4	27.1	+19.4%
2024	4.3	-0.6	0.4	-7.4	-13.4	14.1	-16.3	-7.9	-2.9	-0.6	14.1	25.0	+1.2%
2023	21.6	-20.5	-12.5	-4.7	-3.0	4.8	8.6	-15.1	15.8	-5.4	-10.1	12.1	−16.6%
2022	1.9	0.2	18.1	0.9	-16.7	7.2	1.0	-17.0	2.6	7.1	-13.9	-11.6	−23.8%
2021	57.1	12.5	-8.4	13.6	-10.8	-2.8	6.0	-9.0	2.2	-6.0	1.5	-10.4	+34.5%
2020	4.1	7.3	-34.1	20.6	-1.3	4.9	5.3	4.8	4.0	-2.2	17.3	-4.5	+15.5%
2019	11.5	-8.0	-12.2	1.3	-4.0	5.3	-7.4	-10.3	3.1	-7.4	-3.1	3.0	−27.0%
2018	-16.7	-1.2	-3.2	3.0	-2.5	-3.0	-0.3	2.5	19.5	-4.2	-7.9	-4.1	−19.8%
2017	-0.5	-5.2	-1.4	-1.6	13.6	18.6	-6.5	-15.2	11.9	21.5	13.8	-2.2	+47.7%
2016	-22.1	1.4	15.1	-1.3	0.1	1.9	1.7	1.0	9.0	-27.7	-4.1	11.0	−21.1%
2015	23.9	10.5	-5.4	1.3	14.6	7.5	40.1	-34.0	-18.0	16.0	10.1	-0.8	+55.1%
2014	0.5	4.0	7.6	-14.6	5.1	2.1	9.1	-7.5	11.9	-0.8	-0.8	-0.6	+13.8%
2013	-4.3	-5.2	1.4	2.2	-2.1	2.2	-11.2	22.8	15.4	-5.9	-5.6	1.7	+6.7%
2012	1.1	1.9	13.2	-10.5	17.7	2.5	1.2	-7.4	-6.8	-4.1	-9.8	-9.5	−14.0%
2011	8.1	-11.3	11.7	35.0	-4.3	78.3	-15.3	0.1	-20.9	-2.1	2.1	-12.3	+45.3%
2010	9.4	-3.9	-10.0	4.6	2.2	-10.1	-12.5	3.7	4.6	-0.9	-14.5	18.1	−13.7%
2009	8.4	-23.3	37.7	-4.7	2.2	34.1	-3.2	22.1	22.2	18.2	-9.9	-2.6	+123.5%
2008	0.3	-5.9	2.7	-11.3	8.2	5.2	-0.6	-4.3	-3.6	-21.7	-21.3	-15.3	−53.2%
2007	-4.0	-3.7	-1.3	2.6	2.3	5.1	-33.1	-9.0	17.8	-6.0	-1.0	-11.3	−40.3%

INSD

Insider Activity · ICCC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 17, 2026	Te Boekhorst Paul Francis OlivierChief Executive Officer	Purchase at price 9.50 per share.	8K	$75.96K
Mar 19, 2026	Brigham Michael FDirector	Conversion of Exercise of derivative security at price 5.84 per share.	25K	$146.00K
Dec 3, 2025	Te Boekhorst Paul Francis OlivierChief Executive Officer	Purchase at price 4.87 - 5.50 per share.	9.7K	$49.58K
Dec 2, 2025	Te Boekhorst Paul Francis OlivierChief Executive Officer	Purchase at price 4.87 - 5.04 per share.	9.8K	$48.59K
Nov 24, 2025	Tomsche David ScottDirector	Purchase at price 4.76 per share.	3.3K	$15.55K
Jun 11, 2025	Gathagan Bryan KDirector	Purchase at price 6.32 per share.	1K	$6.32K
Jun 10, 2025	Basse Gloria FDirector	Conversion of Exercise of derivative security at price 4.81 per share.	3.5K	$16.98K

13F

Investors Holding ICCC

latest 13F filings of 29 followed managers

Investors holding ICCC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.7M	0.00%	171.09K	+13%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ICCC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ICCC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About ImmuCell Corporation

Seasonality · ICCC

Insider Activity · ICCC

Congress Trades · ICCC

Investors Holding ICCC

Investors Holding ICCC

Congress Trades · ICCC

Insider Activity · ICCC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About ImmuCell Corporation

Earnings & Dividends

News

Seasonality · ICCC